AbbVie (NYSE:ABBV) 2026 Conference Transcript

AbbVie 2026 Conference Call Summary Company Overview - Company: AbbVie (NYSE: ABBV) - Date: March 10, 2026 - Key Executives: Roopal Thakkar (CSO), Scott Reents (CFO) Key Points Growth Prospects - AbbVie anticipates a revenue of $67 billion in 2026, reflecting strong growth momentum from 2025 [2][3] - The company expects to achieve high single-digit growth through the decade, supported by a robust portfolio of assets [2][3] Product Performance - SKYRIZI and RINVOQ have shown a combined growth of over 20% in the past year, indicating strong market performance [3] - The company has significant room for market share growth, particularly in immunology and neuroscience [4] - The oral CGRPs for migraine, UBRELVY and QULIPTA, are projected to exceed $5 billion in peak sales [5] Financial Performance - AbbVie has expanded its operating margin, with EPS growth exceeding 13% and top-line growth just under 10% [6] - The company continues to invest in R&D, maintaining a budget of 14%-15% of revenue, which has increased by a few billion since 2022 [6] Competitive Landscape - SKYRIZI holds 60% of new patient starts in IBD, with 75% share among naive patients, indicating strong competitive positioning despite concerns about Tremfya [11][12] - The label update for RINVOQ allows for more flexible prescribing, enhancing its competitive edge in the market [14] Pipeline and Future Catalysts - Upcoming readouts include: - RINVOQ in Hidradenitis Suppurativa (HS) and combination studies in IBD [44][45] - Lutikizumab, targeting IL-1 alpha and beta, with potential for significant market impact in HS [44] - T-cell engaging BCMA antibody in multiple myeloma, expected to show a favorable safety profile [46] - Gilgamesh asset in depression, with potential expansion into PTSD [48] M&A and Business Development - AbbVie has conducted over 30 transactions totaling approximately $8 billion in the last two years to enhance its R&D capabilities [63] - The company is open to pursuing quality assets that align with its long-term growth strategy, despite not needing immediate M&A [62][64] Market Positioning - AbbVie is focused on maintaining a strong financial discipline and providing detailed guidance to investors, which sets it apart from competitors [54][56] - The company is positioned for solid growth, with a low P/E-to-growth ratio indicating potential undervaluation in the market [58][61] Additional Insights - The company is optimistic about the efficacy of its new drug candidates, particularly in under-penetrated markets like HS and IBD [71] - AbbVie aims to optimize its pipeline with a focus on combination therapies and innovative treatment approaches [64][65] This summary encapsulates the key insights from AbbVie's conference call, highlighting the company's growth strategies, product performance, financial health, competitive landscape, and future opportunities.